Celldex Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Celldex Therapeutics (NASDAQ:CLDX) reported Q4 earnings with an EPS of $-0.83, missing estimates by -12.0% against an expected $-0.74. Revenue increased by $2.52 million from the same period last year. Despite missing EPS estimates last quarter, the share price increased by 8.0% the following day. Historical earnings performance shows a pattern of missed EPS estimates but varying revenue outcomes.
February 26, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Celldex Therapeutics reported a Q4 EPS of $-0.83, missing estimates by -12.0%, with a revenue increase of $2.52 million from the previous year.
Missing the EPS estimate by -12.0% could lead to a negative short-term impact on CLDX's stock price, as market reactions to earnings misses can be unfavorable. However, the increase in revenue and historical context of share price increase following an earnings miss last quarter suggest a complex impact. The negative score reflects the immediate reaction to missing EPS estimates, but investors should consider the revenue growth and past price resilience in their analysis.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100